Ironwood Pharmaceuticals Inc (IRWD) concluded trading on Thursday at a closing price of $0.59, with 3.89 million shares of worth about $2.29 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -87.56% during that period and on May 15, 2025 the price saw a loss of about -8.41%. Currently the company’s common shares owned by public are about 161.81M shares, out of which, 156.20M shares are available for trading.
Stock saw a price change of -15.07% in past 5 days and over the past one month there was a price change of -17.70%. Year-to-date (YTD), IRWD shares are showing a performance of -86.58% which decreased to -91.12% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.59 but also hit the highest price of $7.11 during that period. The average intraday trading volume for Ironwood Pharmaceuticals Inc shares is 3.17 million. The stock is currently trading -26.15% below its 20-day simple moving average (SMA20), while that difference is down -46.78% for SMA50 and it goes to -81.52% lower than SMA200.
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) currently have 161.81M outstanding shares and institutions hold larger chunk of about 86.14% of that.
The stock has a current market capitalization of $96.18M and its 3Y-monthly beta is at 0.27. It has posted earnings per share of -$0.20 in the same period. It has Quick Ratio of 3.34. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IRWD, volatility over the week remained 10.72% while standing at 12.73% over the month.
Stock’s fiscal year EPS is expected to rise by 1644.75% while it is estimated to increase by 102.88% in next year. EPS is likely to grow at an annualized rate of 141.01% for next 5-years, compared to annual growth of -47.49% made by the stock over the past 5-years.
On April 14, 2025, Citizens JMP Downgrade their recommendations, while on September 09, 2024, Leerink Partners Initiated their ratings for the stock with a price target of $5. Stock get an Equal weight rating from CapitalOne on August 08, 2024.
